Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, Usmani SZ.
Hamadeh IS, et al. Among authors: moore dc.
Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):470-475. doi: 10.1016/j.clml.2021.02.014. Epub 2021 Mar 4.
Clin Lymphoma Myeloma Leuk. 2021.
PMID: 33785299